Loading...
  • cancers
  • In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. (pitchengine.com)
  • prevention
  • Jansen KU, Shaw AR (2004) Human papillomavirus vaccines and prevention of cervical cancer. (springer.com)
  • As one of the first studies to assess multiple aspects of recommendation quality, these findings can inform the many state and national initiatives that aim to improve communication about HPV vaccine so as to address the persistent underuse of a powerful tool for cancer prevention. (aacrjournals.org)
  • Low coverage of human papillomavirus (HPV) vaccine is one of the most pressing problems in cancer prevention ( 1 ). (aacrjournals.org)
  • Public health leaders, including the Centers for Disease Control and Prevention (CDC) and the President's Cancer Panel, have identified improving healthcare providers' communication as a key strategy for raising HPV vaccine coverage ( 1, 2 ). (aacrjournals.org)
  • VLPs
  • The quadrivalent HPV vaccine is a mixture of four HPV type-specific VLPs prepared from the L1 proteins of HPV 6, 11, 16, and 18 combined with an aluminum adjuvant. (cdc.gov)
  • recommendations
  • Screening recommendations might also be modified based on the longer-term follow-up data and cost-effectiveness considerations, but some level of screening is likely to be required for decades following the implementation of vaccine programs. (springer.com)
  • The HPV vaccine: are dosing recommendations being followed? (wiley.com)
  • dose
  • The vaccine is administered by intramuscular injection, and the recommended schedule is a 3-dose series with the second and third doses administered 2 and 6 months after the first dose. (cdc.gov)
  • Despite an excellent safety profile ( 2 ), mounting evidence of effectiveness ( 3, 4 ), and national guidelines for routine administration ( 5 ), only 38% of adolescent girls and 14% of adolescent boys complete the three-dose HPV vaccine series ( 6 ). (aacrjournals.org)
  • HPV vaccine coverage by dose (1, 2 and 3), age and state of residence, using Australian Bureau of Statistics estimates of resident populations as the denominator. (mja.com.au)
  • 2 The vaccine is a three-dose course given over 6 months, delivered to girls at school (aged 12-17 years) between April 2007 and December 2008, with courses to be completed by end December 2009. (mja.com.au)
  • Most adolescents 9 through 14 years of age should get HPV vaccine as a two-dose series with the doses separated by 6 to 12 months. (floridahealthfinder.gov)
  • Anyone who has had a severe (life-threatening) allergic reaction to a dose of HPV vaccine should not get another dose. (floridahealthfinder.gov)
  • CRPS
  • EMA has now completed its review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines. (europa.eu)
  • The CHMP concurred that the available evidence does not support that CRPS and POTS are caused by HPV vaccines. (europa.eu)
  • There have been reports of two syndromes, CRPS and POTS, in girls who have been given HPV vaccines. (europa.eu)
  • PRAC concluded: "the available evidence does not support that CRPS* and POTS** are caused by HPV vaccines. (perssupport.nl)
  • peptides
  • Overlapping peptides comprising amino acids (aa) 2 to 22 (hereafter, chimera or peptide 2-22), 13 to 107, 18 to 31, 17 to 36, 35 to 75, 75 to 112, 115 to 154, 149 to 175, and 172 to 200 of HPV type 16 (HPV16) L2 were genetically engineered into the DE surface loop of bovine papillomavirus type 1 L1 VLP. (nih.gov)
  • therapeutic
  • These findings suggest that the HPV vaccine may have therapeutic utility for patients with squamous cell carcinomas who are poor surgical candidates, have multiple lesions, or defer surgery. (ascopost.com)
  • Therapeutic HPV vaccines (THV), therefore, correspond to a currently unmet medical need. (aacrjournals.org)
  • Safety
  • The book outlines the pathobiology and immunology of human papillomavirus, the clinical data and safety and tolerance issues. (future-science-group.com)
  • The safety of these vaccines, as with all medicines, will continue to be carefully monitored and will take into account any future new evidence of side effects that becomes available. (europa.eu)
  • The purpose of this study is to determine the safety of and immune response to a new human papillomavirus (HPV) vaccine in HIV (Human immunodeficiency virus) infected children between the ages of 7 and 12 years. (clinicaltrials.gov)
  • We hypothesized that prior exposure to opinions rejecting the safety or value of HPV vaccines would be associated with an increased risk of posting similar opinions and tested this hypothesis by analyzing temporal sequences of messages posted on Twitter (tweets). (jmir.org)
  • findings
  • These results extend recent findings from a randomized control trial based on an HPV DNA vaccine, which induced regression of HPV16- or HPV18-positive CIN2/3 in 48.2% of cases compared with a spontaneous regression rate of 30% in the placebo arm ( 3 ). (aacrjournals.org)
  • Translation of basic scientific findings into practical patient outcomes is a significant exercise even when the goal is conceptually straightforward, as in the development of a vaccine for an infectious disease. (jimmunol.org)
  • implementation
  • Aim 3 will test the hypothesis that simultaneous implementation of interventions targeting individual, interpersonal, and organizational factors will have a synergistic effect on HPV vaccine delivery rates. (centerwatch.com)
  • viral
  • A different HPV DNA vaccine administered in 9 CIN3 patients also induced complete regression of lesions and viral clearance in 7 patients ( 4 ). (aacrjournals.org)
  • adolescents
  • The quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine to be tested in this study was safe and generally well tolerated in previous studies conducted in healthy and HPV-exposed adolescents, young adults, and older women. (clinicaltrials.gov)
  • lesions
  • A recombinant Modified Vaccinia Ankara (MVA) HPV16 E6 and E7 cDNA vaccine achieved cytologic clearance of CIN2/3 lesions and clearance of HPV16 virus in previously infected tissue in 7 of 10 patients ( 5 ). (aacrjournals.org)
  • The vaccine itself did not appear to be the critical element to explain the differential clinical activity of THV, as the clinical impact of HPV vaccines was only observed in patients with premalignant HPV-associated lesions, whereas none of the vaccines displayed any clinical activity in established cancer. (aacrjournals.org)